Docoh
Loading...

KALA Kala Pharmaceuticals

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases.

Company profile

KALA stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 Aug 21
20 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 144.64M 144.64M 144.64M 144.64M 144.64M 144.64M
Cash burn (monthly) (positive/no burn) (positive/no burn) 9.68M 9.35M 7.2M 8.82M
Cash used (since last report) n/a n/a 35.65M 34.43M 26.52M 32.47M
Cash remaining n/a n/a 108.98M 110.21M 118.11M 112.16M
Runway (months of cash) n/a n/a 11.3 11.8 16.4 12.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Oct 21 Myers C. Daniel Stock Option Common Stock Grant Acquire A No No 2.21 42,000 92.82K 42,000
29 Jun 21 Chen Hongming Common Stock Sell Dispose S No Yes 5.56 5,548 30.85K 235,015
28 Jun 21 Brazzell Romulus K Common Stock Sell Dispose S No Yes 5.77 3,034 17.51K 300,962
28 Jun 21 Trachtenberg Eric Common Stock Sell Dispose S No Yes 5.77 2,452 14.15K 126,115

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

49.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 106 117 -9.4%
Opened positions 13 16 -18.8%
Closed positions 24 20 +20.0%
Increased positions 45 30 +50.0%
Reduced positions 21 36 -41.7%
13F shares
Current Prev Q Change
Total value 223.61M 349.77M -36.1%
Total shares 32.21M 36.8M -12.5%
Total puts 299.9K 513.8K -41.6%
Total calls 304.9K 247K +23.4%
Total put/call ratio 1.0 2.1 -52.7%
Largest owners
Shares Value Change
Ra Capital Management 10.87M $57.64M 0.0%
Orbimed Advisors 5.47M $28.97M 0.0%
BLK Blackrock 3.72M $19.71M +12.1%
Vanguard 2.2M $11.68M +5.2%
Caxton 1.7M $9.04M +19.2%
STT State Street 822.29K $4.36M +17.5%
Geode Capital Management 753.3K $3.99M +10.4%
Samsara BioCapital 601.16K $3.19M 0.0%
NTRS Northern Trust 490.09K $2.6M +9.0%
Dimensional Fund Advisors 399.46K $2.12M -14.4%
Largest transactions
Shares Bought/sold Change
Eventide Asset Managment 0 -3.45M EXIT
Vivo Capital 0 -786.88K EXIT
Millennium Management 28.38K -672.29K -95.9%
FMR 1 -574.9K -100.0%
BLK Blackrock 3.72M +402.07K +12.1%
Pictet Asset Management 392.11K +392.11K NEW
Two Sigma Advisers 0 -326.8K EXIT
UBS UBS Group AG - Registered Shares 345.07K +287.83K +502.9%
Caxton 1.7M +274.83K +19.2%
ACT Capital Management, LLLP 190K +190K NEW

Financial report summary

?
Management Discussion
  • Product revenues, net was $3.1 million for the three months ended June 30, 2021, consisting of $1.7 million from EYSUVIS sales and $1.4 million from INVELTYS sales, compared to $0.8 million from INVELTYS sales for the three months ended June 30, 2020. There were no sales of EYSUVIS in the three months ended June 30, 2020. The increase in product revenues, net of $2.3 million was driven primarily by sales of EYSUVIS, which we began shipping to wholesalers in the United States in late December 2020, an increase in the total units of INVELTYS sold in the three months ended June 30, 2021 as well as a higher per unit gross selling price of INVELTYS as compared to those sold during the three months ended June 30, 2020. These increases in INVELTYS sales were partially offset by higher estimated reserves per unit during the three months ended June 30, 2021 as compared to those estimated during the three months ended June 30, 2020. We expect product revenues to increase if and as we increase our market share and obtain and maintain coverage and adequate reimbursement for EYSUVIS and INVELTYS from third-party payors; however, revenues could continue to be negatively impacted in 2021 as a result of the COVID-19 pandemic.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: bore, extinguishment, rare, unaccreted, unamortized
Removed: accreted, affiliate, consolidate, covenant, instructed, instrument, leaseback, merge, NaN, warrant